Top

Supportive Care in Cancer

Published in:

01-11-2011 | Original Article

Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis

Authors: George Dranitsaris, Haytham Khoury

Published in: Supportive Care in Cancer | Issue 11/2011

Abstract

Introduction

Invasive fungal infections (IFI) remain a clinical concern in hematological patients with prolonged neutropenia because they are a major cause of morbidity and mortality. In a recent randomized trial, prophylaxis with posaconazole was associated with fewer IFI and related deaths relative to a fluconazole or itraconazole (Flu/Itra) control group (p < 0.001). In the current study, a cost effectiveness analysis was conducted to estimate the economic value of posaconazole as an alternative to Flu/Itra when used to prevent IFI in this patient population.

Methods

A decision analysis model was developed using clinical and economic data from randomized comparative trials, the economic literature, and from expert opinion. The data were then used to estimate the incremental cost per life year saved with oral posaconazole prophylaxis relative to Flu/Itra from the Canadian provincial health care system perspective. The base case results were then tested with a sensitivity analysis which evaluated extremes in the incidence of IFI as well as variations in their cost of management.

Results

Prophylaxis with posaconazole provides increased efficacy and an overall cost savings of approximately $Can4,259 per patient. Despite variations in the base case parameters, the sensitivity analysis suggested stability in the primary findings. Posaconazole was associated with an overall cost savings (range = $Can1,765 to $Can4,505) in all of the scenarios evaluated. Optimal cost effectiveness was obtained because the drug was able to avoid the more resource intensive Aspergillus infections.

Conclusions

Prophylaxis with posaconazole in cancer patients with prolonged neutropenia is not only cost effective but also cost saving. The economic benefits were due to the drug’s ability to reduce the incidence of high cost fungal infections, particularly Aspergillus species.

Bow EJ (2008) Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br J Haematol 140:133–152PubMedCrossRef

Bow EJ, Wingard JR, Bowden RA (2003) Infectious complications in patients receiving cytotoxic therapy for acute leukemia: history, background and approaches to managment. Management of infection in oncology patients. Martin Dunitz, London, pp 71–104

Nucci M, Anaissie E (2001) Revisiting the source of candidemia: skin or gut? Clin Infect Dis 33:1959–1967PubMedCrossRef

Blijlevens NM, Donnelly JP, De Pauw BE (2002) Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 117:259–264PubMedCrossRef

Bow EJ, Meddings JB (2006) Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia 20:2087–2092PubMedCrossRef

Gerson SL, Talbot GH, Hurwitz S et al (1984) Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100:345–351PubMed

Burwen DR, Lasker BA et al (2001) Invasive aspergillosis outbreak on a hematology–oncology ward. Infect Control Hosp Epidemiol 22:45–48PubMedCrossRef

Herbrecht R, Natarajan-Amé S, Letscher-Bru V, Canuet M (2004) Invasive pulmonary aspergillosis. Semin Respir Crit Care Med 25:191–202PubMedCrossRef

Bow EJ (2009) Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol 46:259–268PubMedCrossRef

10.

Bow EJ, Laverdiere M, Lussier N et al (2002) Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 94:3230–3246PubMedCrossRef

11.

Robenshtok E, Gafter-Gvili A, Goldberg E et al (2000) Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 25:5471–5489CrossRef

12.

Nucci M, Biasoli I, Akiti T, et al. (2000) A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 30:300–305.

13.

Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359PubMedCrossRef

14.

Morrissey CO, Bardy PG, Slavin MA et al (2008) Diagnostic and therapeutic approach to persistent or recurrent fevers of unknown origin in adult stem cell transplantation and haematological malignancy. Intern Med J 38:477–95PubMedCrossRef

15.

Martino R, Viscoli C (2006) Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 132:138–54PubMedCrossRef

16.

van Burik JA, Ratanatharathorn V, Stepan DE et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407–16PubMedCrossRef

17.

Wilson LS, Reyes CM, Stolpman M et al (2002) The direct cost and incidence of systemic fungal infections. Value Health 5:26–34PubMedCrossRef

18.

O’Sullivan AK, Pandya A, Papadopoulos G et al (2009) Cost effectiveness of posaconazole versus fluconazole or intraconazole in the presention of invasive fungal infections among neutropenic patients in the United States. Value Health 12:666–673PubMedCrossRef

19.

Hillner BE, Smith TJ (2009) Efficacy does not necessarily translate to cost effectiveness. A case study in the challenges associated with 21st century cancer drug pricing. J Clin Oncol 27:2111–3PubMedCrossRef

20.

Fojo T, Grandy C (2009) How much is a life worth: cetuximab, non small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101:1044–48PubMedCrossRef

21.

Walsh TJ, Anaissie EJ, Denning DW et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–60PubMedCrossRef

Title: Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis
Authors: George Dranitsaris
Haytham Khoury
Publication date: 01-11-2011
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 11/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-010-1022-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2011

Nutritional status of patients with locally advanced pancreatic cancer: a pilot study

Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score

Psychometric evaluation and feasibility of the Greek Pittsburgh Sleep Quality Index (GR-PSQI) in patients with cancer receiving chemotherapy

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists

“When patients and families feel abandoned”

Keynote webinar | Spotlight on antibody–drug conjugates in cancer